riSCC:皮肤鳞状细胞癌不良结局的个性化风险预测模型
riSCC在所有结局上的区分度均优于AJCC第8版和Brigham and Women's Hospital的T分期系统,5年C指数从局部复发的0.74到疾病特异性死亡的0.87。
要点
- riSCC模型可对皮肤鳞癌不良结局提供细粒度风险分层。
- riSCC预测性能优于AJCC第8版和Brigham T分期系统。
- 5年C指数:局部复发0.74,疾病特异性死亡0.87。
核心结论
- riSCC预后模型相比T分期系统可提供更精细的风险估计并改善皮肤鳞癌重要结局的分层。
研究设计与样本
- 回顾性12中心跨国队列研究,纳入1991至2023年皮肤鳞状细胞癌。
- 采用Fine-Gray模型并结合逆概率治疗加权,训练最终模型用于前瞻性使用和估计风险比。
主要发现
- riSCC预后模型在所有结局上的预测性能均优于AJCC第8版和Brigham and Women's Hospital的T分期系统。
- 5年C指数范围从局部复发的0.74到疾病特异性死亡的0.87。
关键数值与推荐
- 5年C指数:局部复发0.74,疾病特异性死亡0.87。
- riSCC在所有结局上均优于AJCC第8版和Brigham and Women's Hospital的T分期系统。
临床怎么用
- riSCC可辅助临床对皮肤鳞癌患者进行更精细的风险分层,指导个体化随访与治疗决策。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous squamous cell carcinoma (CSCC) is a prevalent disease for which improved risk stratification strategies are needed. OBJECTIVE: To develop a novel prognostic model (herein "riSCC") for CSCC and compare riSCC performance to Brigham and Women's Hospital and American Joint Committee on Cancer Staging eighth edition T staging systems. METHODS: Retrospective 12-center, multinational cohort study of CSCCs from 1991 to 2023. Clinical and pathologic risk factors, treatments, and outcomes were collected. Fine-Gray model was employed for each outcome with inverse probability of treatment weighting. A final model was trained for prospective use and estimation of hazard ratios. RESULTS: Twenty-three thousand one hundred sixty-six localized CSCC tumors were included. riSCC prognostic model performed superiorly to American Joint Committee on Cancer eighth edition and Brigham and Women's Hospital T staging for all outcomes. At 5 years, the C-index for riSCC ranged from 0.74 for local recurrence to 0.87 for disease specific death. LIMITATIONS: Retrospective study design. CONCLUSION: riSCC prognostic model offers fine-grained risk estimates and improved stratification for important CSCC outcomes compared to T staging systems.
引用
- Jambusaria-Pahlajani A, Jeanselme V, Wang DM, et al. riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2025. PMID: 40024391. doi:10.1016/j.jaad.2025.02.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。